Literature DB >> 10861265

Imbalance of stromelysin-1 and TIMP-1 in the mucosal lesions of children with inflammatory bowel disease.

R B Heuschkel1, T T MacDonald, G Monteleone, M Bajaj-Elliott, J A Smith, S L Pender.   

Abstract

BACKGROUND: Degradation of the extracellular matrix and ulceration of the mucosa are major features of inflammatory bowel disease (IBD). One of the most important enzymes in degrading the matrix and produced in excess by cytokine activated stromal cells, is stromelysin-1. The activity of stromelysin-1 is controlled by tissue inhibitor of metalloproteinase (TIMP-1), its natural inhibitor. In model systems excess stromelysin-1 produces mucosal degradation.
METHODS: Quantitative competitive RT-PCR was used to analyse stromelysin-1 and TIMP-1 transcripts; western blotting was used to measure the amount of stromelysin-1 and TIMP-1 protein in biopsy samples from children with IBD.
RESULTS: In biopsies from patients with active Crohn's disease (n=24), ulcerative colitis (n=23), and controls (n=16), TIMP-1 transcripts and protein were abundant and unchanged. Stromelysin-1 transcripts and protein were markedly elevated in mucosal biopsies obtained from inflamed sites of patients with active IBD but were not elevated in adjacent endoscopically normal mucosa (n=10). Elevated levels of stromelysin-1 transcripts in active Crohn's disease (n=5) returned to normal levels following treatment with enteral nutrition.
CONCLUSIONS: Stromelysin-1 is markedly overexpressed at inflamed sites in patients with IBD whereas TIMP-1 remains unaltered. Excess stromelysin-1 is likely to be responsible for loss of mucosal integrity in IBD.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10861265      PMCID: PMC1727949          DOI: 10.1136/gut.47.1.57

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  38 in total

Review 1.  Activation of extracellular matrix metalloproteases by proteases and organomercurials.

Authors:  G A Grant; G I Goldberg; S M Wilhelm; C He; A Z Eisen
Journal:  Matrix Suppl       Date:  1992

Review 2.  Matrix metalloproteinases and their inhibitors in connective tissue remodeling.

Authors:  J F Woessner
Journal:  FASEB J       Date:  1991-05       Impact factor: 5.191

3.  Development and validation of a pediatric Crohn's disease activity index.

Authors:  J S Hyams; G D Ferry; F S Mandel; J D Gryboski; P M Kibort; B S Kirschner; A M Griffiths; A J Katz; R J Grand; J T Boyle
Journal:  J Pediatr Gastroenterol Nutr       Date:  1991-05       Impact factor: 2.839

4.  Distribution of the matrix metalloproteinases stromelysin, gelatinases A and B, and collagenase in Crohn's disease and normal intestine.

Authors:  C J Bailey; R M Hembry; A Alexander; M H Irving; M E Grant; C A Shuttleworth
Journal:  J Clin Pathol       Date:  1994-02       Impact factor: 3.411

5.  Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease.

Authors:  S H Murch; C P Braegger; J A Walker-Smith; T T MacDonald
Journal:  Gut       Date:  1993-12       Impact factor: 23.059

6.  Structure and expression in breast tumors of human TIMP-3, a new member of the metalloproteinase inhibitor family.

Authors:  J A Uría; A A Ferrando; G Velasco; J M Freije; C López-Otín
Journal:  Cancer Res       Date:  1994-04-15       Impact factor: 12.701

7.  Clinical evaluation of serum tissue inhibitor of metalloproteinases-1 levels in patients with liver diseases.

Authors:  D A Muzzillo; M Imoto; Y Fukuda; Y Koyama; S Saga; Y Nagai; T Hayakawa
Journal:  J Gastroenterol Hepatol       Date:  1993 Sep-Oct       Impact factor: 4.029

8.  Cytokine messenger RNA profiles in inflammatory bowel disease mucosa detected by polymerase chain reaction amplification.

Authors:  K L Isaacs; R B Sartor; S Haskill
Journal:  Gastroenterology       Date:  1992-11       Impact factor: 22.682

9.  Selective regulation of metalloproteinase inhibitor (TIMP-1) by oncostatin M in fibroblasts in culture.

Authors:  C D Richards; M Shoyab; T J Brown; J Gauldie
Journal:  J Immunol       Date:  1993-06-15       Impact factor: 5.422

10.  Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family.

Authors:  W G Stetler-Stevenson; H C Krutzsch; L A Liotta
Journal:  J Biol Chem       Date:  1989-10-15       Impact factor: 5.157

View more
  40 in total

Review 1.  Small therapeutic molecules for the treatment of inflammatory bowel disease.

Authors:  S J H van Deventer
Journal:  Gut       Date:  2002-05       Impact factor: 23.059

2.  Basement membrane components.

Authors:  A C Y Li; R P H Thompson
Journal:  J Clin Pathol       Date:  2003-12       Impact factor: 3.411

3.  A place for TACE.

Authors:  S J H van Deventer
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

Review 4.  Fistulising Crohn's disease: MMPs gone awry.

Authors:  D Schuppan; T Freitag
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

Review 5.  Immunopathogenesis of IBD: current state of the art.

Authors:  Heitor S P de Souza; Claudio Fiocchi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-12-02       Impact factor: 46.802

6.  Expression of matrix metalloproteinases and tissue inhibitor metalloproteinases increases in X-irradiated rat ileum despite the disappearance of CD8a T cells.

Authors:  Carine Strup-Perrot; Marie-Catherine Vozenin-Brotons; Marie Vandamme; Christine Linard; Denis Mathé
Journal:  World J Gastroenterol       Date:  2005-10-28       Impact factor: 5.742

7.  Expression of matrix metalloproteinase-1 and tumor necrosis factor-alpha in ulcerative colitis.

Authors:  Ying-De Wang; Jing-Wei Mao
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

8.  Upregulation of matrix metalloproteinases in a model of T cell mediated tissue injury in the gut: analysis by gene array and in situ hybridisation.

Authors:  M T Salmela; T T MacDonald; D Black; B Irvine; T Zhuma; U Saarialho-Kere; S L F Pender
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

9.  Expression and localisation of matrix metalloproteinases and their natural inhibitors in fistulae of patients with Crohn's disease.

Authors:  T Kirkegaard; A Hansen; E Bruun; J Brynskov
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

10.  Attenuation of dextran sodium sulphate induced colitis in matrix metalloproteinase-9 deficient mice.

Authors:  Alfredo Santana; Carlos Medina; Maria-Cristina Paz-Cabrera; Federico Díaz-Gonzalez; Esther Farré; Antonio Salas; Marek-W Radomski; Enrique Quintero
Journal:  World J Gastroenterol       Date:  2006-10-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.